INVESTOR RELATIONS

Stock price

NYSEVAR

$3.2B
FY 2019 REVENUES
10%
REVENUES GROWTH IN FY 2019
9%
ONCOLOGY ORDERS GROWTH IN FY 2019
5%
NON-GAAP EPS ¹ GROWTH IN FY 2019

$3.2B
FY 2019 REVENUES
10%
REVENUES GROWTH IN FY 2019
9%
ONCOLOGY ORDERS GROWTH IN FY 2019
5%
NON-GAAP EPS ¹ GROWTH IN FY 2019

Press Releases

Sep 16, 2020

Varian Expects to Benefit from the Extension of Medical Linear Accelerators Tariff Exclusion in China

Varian (NYSE: VAR) has received notice from the Customs Tariff Commission of the State Council of China that the first exclusion of the additional tariffs China imposed on US products will expire...

Sep 15, 2020

Varian Drives Next Evolution of Proton Treatment Planning with Eclipse v16.1

Highlights: Integration of Dual Energy CT (DECT) images in the Eclipse planning process reduces range uncertainty and helps clinicians' spare healthy tissue. Graphics Processing Unit (GPU)...

Sep 14, 2020

Varian Announces Appointment of Chris Toth as President and Chief Operating Officer

Varian (NYSE: VAR) today announced the following leadership appointments, effective October 5, 2020: Chris Toth, Varian Oncology Systems President, has been appointed to the newly created role of...

Sep 10, 2020

Varian Announces Goshen Center for Cancer Care Treats First Patient with Ethos® Therapy, Expanding Access to Personalized Cancer Care

Varian (NYSE: VAR) today announced the Goshen Center for Cancer Care in Goshen, Ind., treated its first patient with Ethos™ therapy, marking the first availability of this advanced cancer...

View all press releases

Upcoming Events

No events to display

View all events

Past Events

Third Quarter FY2020 Earnings Results Conference Call

Wednesday, August 5, 2020

1:30pm PDT

Canceled Third Quarter Conference Call in Light of Pending Transaction with Siemens Healthineers

Goldman Sachs Global Virtual Healthcare Conference

Tuesday, June 9, 2020

11:20am EDT